Abstract
The lack of specificity of chemotherapy and external beam radiation frequently results in toxicity to normal organs, limiting doses to below those at which tumor control would be reached. Because of its potential for increasing the specificity of cytotoxic effects, radioimmunotherapy is a conceptually appealing approach for cancer treatment. Assuming that an antibody can be generated that is specific for the cancer in question, then combining this antibody with an appropriate radionuclide should yield a treatment modality with a high therapeutic index. Unfortunately, with the exception of highly radiosensitive tumors (Eary et al. 1990), results from most clinical trials indicate that the promise of antibody-mediated radiotherapy has not been realized. The lack of efficacy for radioimmunotherapy is not surprising since only a small fraction of labeled antibody has been reported to localize in tumor following intravenous administration (generally between 0.001% and 0.01% injected dose per gram), and significant accumulation in normal tissues also has been observed (Carrasquillo 1989; Zalutsky et al. 1990).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Aaij C, Tschroots WRJM, Lindner L, Feltkamp TEW (1975) The preparation of astatine labelled proteins. Int J Appl Radiat Isot 26: 25–30
Armour EP, Wang Z, Corry PM, Martinez A (1991) Sensitization of rat 9L gliosarcoma cells to low dose rate irradiation by long duration 41°C hyperthermia. Cancer Res 51: 3088–3095
Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50: 4478–4484
Bourdon M, Wikstrand CJ, Furthmayr H, Matthews T, Bigner DD (1983) Human glioma mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43: 2796–2805
Carrasquillo JA (1989) Radioimmunoscintigraphy with polyclonal and monoclonal antibodies. In: Zalutsky MR (ed) Antibodies in radiodiagnosis and therapy. CRC Boca Raton, pp 169–198
Cobb LM, Humm JL (1986) Radioimmunotherapy of malignancy using antibody targeted radionuclides. Br J Cancer 54: 863–870
Colapinto EV, Zalutsky MR, Archer GE, Noska MA, Friedman HS, Bigner DD (1990) Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab′)2 fragments of monoclonal antibody Mel-14. Cancer Res 50: 1822–1827
Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, Larson SM, Schlom J (1987) Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Cancer Res 47: 4218–4224
Cope DA, Dewhirst MW, Friedman HS, Bigner DD, Zalutsky MR (1990) Enhanced delivery of a monoclonal antibody F(ab′)2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res 50: 1803–1809
Davies C deL, Rofstad EK, Lindmo T (1985) Hyperthermia-induced changes in antigen expression on human FME melanoma cells. Cancer Res 45: 732–737
Eary JF, Press OW, Badger CC, Durack LD, Richter KY, Addison SJ, Krohn KA, Fisher DR, Porter BA, Williams DL, Martin PJ, Appelbaum FR, Levy R, Brown SL, Miller RA, Nelp WB, Bernstein ID (1990) Imaging and treatment of B-cell lymphoma. J Nucl Med 31: 1257–1268
Friedman AM, Zalutsky MR, Wung W, Buckingham F, Harper PV Jr, Scherr GH, Wainer B, Hunter RL, Appelman EH, Rothberg RM, Fitch FW, Stuart FP, Simonian SJ (1977) Preparation of a biologically stable and immunogenically competent astatinated protein. Int J Nucl Med Biol 4: 219–224
Fuchs HE, Archer GE, Colvin OM, Bigner SH, Schuster JM, Fuller GN, Muhlbaier LH, Schold SC Jr, Friedman HS, Bigner DD (1990) Activity of intrathecal 4-hydroperoxy-cyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res 50: 1954–1959
Garg PK, Harrison CL, Zalutsky MR (1990) Comparative tissue distribution of the alpha emitter 211At and 131I as labels of a monoclonal antibody and F(ab′)2 fragment. Cancer Res 50: 3514–3520
Hall EJ (1993) Radiobiology for the radiologist, 4th edn. Lippincott, Philadelphia, pp 161–177
Humm JL (1987) A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int J Radiat Oncol Biol Phys 13: 1767–1773
Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE, Friedman HS, Kwatra MM, Bigner SH, Bigner DD (1990) Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 87: 4207–4211
Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48:7022–7032
Jain RK, Baxter LT (1988) Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure. Cancer Res 48: 7022–7032
Jain RK, Ward-Hartley K (1984) Tumor blood flow: characterization, modifications and role in hyperthermia. IEEE Trans Sonics Ultrasonics 31: 504–526
Kampf G (1988) Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol Radiother 29: 631–658
Kozak RW, Atcher RW, Gansow OA, Friedman AM, Hines JJ, Waldmann TA (1986) Bismuth-212-labeled anti-Tac monoclonal antibody: α-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc Natl Acad Sci USA 83: 474–478
LeBerthon B, Khawli LA, Alauddin M, Miller GK, Charak BS, Mazumder A, Epstein AL (1991) Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate. Cancer Res 51: 2694–2698
Leunig M, Goetz AE, Dellian M, Zetterer G, Gamarra F, Jain RK, Messmer K (1992) Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 52: 487–490
Macklis RM, Kinsey BM, Kassis Al, Ferrara JLM, Atcher RW, Hines JJ, Coleman CN, Adelstein SJ, Burakoff SJ (1988) Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 240: 1024–1026
Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL (1992) Cellular kinetics, dosimetry, and radiobiology of α-particle radioimmunotherapy: induction of apoptosis. Radiat Res 130: 220–226
Narula AS, Zalutsky MR (1989) No-carrier-added astatination of N-succinimidyl-3- (tri-n-butylstannyl)benzoate ( ATE) via electrophilic destannylation. Radiochim Acta 47: 131–135
Overgaard J (1989) The current and potential role of hyperthermia in radiotherapy. Int J Radiat Oncol Biol Phys 16: 535–549
Schuster J, Zalutsky MR, Noska MA, Dodge R, Bigner DD, Dewhirst MW (1994) Hyperthermic modulation of radiolabeled antibody uptake in human glioma xenograft and normal tissue. Int J Hyperthermia (in press)
Shrivastav S, Schlom J, Raubitschek A, Molinolo A, Simpson J, Hand PA (1989) Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts. Int J Radiat Oncol Biol Phys 16: 721–729
Song CW (1984) Effect of local hyperthermia on blood flow and microenvironment: a review. Cancer Res 44 Suppl:4721s–4730s
Turkington TG, Zalutsky MR, Jaszczak RJ, Garg P, Vaidyanathan G, Coleman RE (1993) Measuring astatine-211 distributions with SPECT. Phys Med Biol 38: 1121–1130
Vaughan ATM, Fremlin JH (1978) The preparation of astatine labelled proteins using an electrophilic reaction. Int J Nucl Med Biol 5: 229–230
Visser GWM, Diemer EL, Kaspersen FM (1979) The preparation and stability of astatotyrosine and astatoiodotyrosine. Int J Appl Radiat Isot 30: 749–752
Wong JY, Mivechi NF, Paxton RJ, Williams LE, Beatty BG, Beatty JD, Shively JE (1989) The effects of hyperthermia on tumor carcinoembryonic antigen expression. Int J Radiat Oncol Biol Phys 17: 803–808
Zalutsky MR, Narula AS (1987) A method for the radiohalogenation of proteins resulting in decreased thyroid uptake of radioiodine. Appl Radiat Isot 38: 1051–1055
Zalutsky MR, Narula AS (1988a) Astatination of proteins using an N-Succinimidyl tri-n-butylstannylbenzoate intermediate. Appl Radiat Isot 39: 227–232
Zalutsky MR, Narula AS (1988b) Radiohalogenation of a monoclonal antibody using an N-succinimidyl 3-(tri-n-butylstannyl)benzoate intermediate. Cancer Res 48: 1446–1450
Zalutsky MR, Noska MA, Colapinto EV, Garg PK, Bigner DD (1989a) Enhanced tumor localization and in vivo stability of a monoclonal antibody radioiodinated using N-succinimidyl-3-(tri-n-butylstannyl)benzoate. Cancer Res 49: 5543–5549
Zalutsky MR, Garg PK, Friedman HS, Bigner DD (1989b) Labeling monoclonal antibodies and F(ab′)2 fragments with the alpha particle emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc Natl Acad Sci USA 86: 7149–7153
Zalutsky MR, Moseley RP, Benjamin JC, Colapinto EV, Fuller GN, Coakham HB, Bigner DD (1990) Monoclonal antibody and F(ab′)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 50: 4105–4110
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Zalutsky, M.R., Schuster, J.M., Garg, P.K., Archer, G.E., Dewhirst, M.W., Bigner, D.D. (1996). Two Approaches for Enhancing Radioimmunotherapy: ∝ Emitters and Hyperthermia. In: Sautter-Bihl, ML., Bihl, H., Wannenmacher, M. (eds) Systemic Radiotherapy with Monoclonal Antibodies. Recent Results in Cancer Research, vol 141. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79952-5_7
Download citation
DOI: https://doi.org/10.1007/978-3-642-79952-5_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-79954-9
Online ISBN: 978-3-642-79952-5
eBook Packages: Springer Book Archive